T-SPeC Surgical System

About Swan Valley Medical

Swan Valley Medical, Incorporated was founded in 2006 with corporate headquarters in Bigfork, Montana with R&D, manufacturing and distribution facilities centrally located in Denver, Colorado. This established mid-stage privately held U.S. based medical device company has successfully developed two unique, proprietary, patented, disposable, high-end, surgical instruments for minimally invasive procedures in the urological medical device segment and holds 13 U.S. and international patents with 6 patents pending. The Company is preparing for mass adoption with increased worldwide dis- tribution and ramp-up in sales and production.

Click for More Information

To download the T-SPeC Surgical System Brochure, click here

About the T-SPeC Surgical System

T-SPeC®, the Company’s first instrument is a disruptive technology with a compelling, safer, lower overall procedure cost, value proposition, with no comparable products in the market. With the T-SPeC®, the Company is currently redefining the market from a low-cost catalog market with high mortality and morbidity (4.4% and 29% respectively) to a high-end single-use surgical instrument market with a profound impact on mortality and morbidity (0% and 1.6% respectively) with significant total procedure cost reductions. The Company’s technology replaces an open surgery and percutaneous procedure with a 5-minute minimally invasive procedure. T-SPeC® will change the current practice from the O.R. setting to lower-cost site-of-care in clinics and Ambulatory Surgery Centers. When compared to transurethral catheterization, the T-SPeC® has a 64% lower infection rate, with a predicted impact to the total bottom-line of hospitals by reducing in-hospital infection rates due to Catheter-Associated Urinary Tract Infections, which are no longer reimbursed under the Affordable Care Act, resulting in overall cost reductions for Hospital-Acquired Infections. The worldwide annual market for T-SPeC® is currently $1.7 Billion with significant growth projected to $3 Billion by 2019. LithoPro™, the Company’s second surgical instrument, is scheduled for launch in Q1 of 2016 with a worldwide annual market of $3.1 Billion with significant growth projected to be $4.3 Billion by 2019. There are no LithoPro™ comparable products in the market. Both instruments have an obese patient model, eliminating the open procedure as the only other option for treating this “large” patient population.

Click for More Information